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Abstract
Quality by Design (QbD) is a systematic, risk-based approach to pharmaceutical 
product and manufacturing development, which uses quality-improving scientific 
methods upstream in the research, development, and design phases, in order to 
assure that quality and safety are designed into product at as early stage as possible. 
This work focuses on the state-of-the-art applications of the QbD principles in 
the development of liposomes. The QbD approach has recently been proposed as 
a useful tool to obtain higher-quality liposomal products, as their development is 
a challenging task, involving intricate formulation and manufacturing processes. 
Thus, the current strategies to define the relationship between the critical mate-
rial attributes or process parameters and product critical quality attributes and to 
establish the design space are overviewed. Additionally, the current characteriza-
tion methodologies are described, as part of the control strategy required within the 
QbD paradigm.
Keywords: liposomes, Quality by Design, critical quality attributes, design space, 
quality control
1. Introduction
In the recent years, the Quality by Design (QbD) concept has gained importance 
in drug development and drug manufacturing. QbD is recommended by the drug 
regulatory agencies (FDA—Food and Drug Administration and EMA—European 
Medicines Agency) to improve the quality of pharmaceutical products.
For the pharmaceutical products, quality is regarded as a mandatory topic 
and must be assured for all. Pharmaceutical products’ quality is ensured through 
the ability to get the therapeutic benefit mentioned on the label and through the 
absence of contamination [1, 2]. Product quality refers to performance, robustness, 
trustworthiness, and has to be built into it [3]. To ensure the quality of a product, 
scientific approaches such as QbD can be implemented. The concept of QbD was 
first defined a few decades ago by Dr. Joseph M. Juran, a well-known pioneer of 
quality, and emphasizes the design of a product and manufacturing process to reach 
a certain predefined quality [1, 2, 4]. According to Dr. Juran, quality should be built 
into a product, and the way in which a product is designed is accountable for most 
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issues related to its quality. Dr. Juran believed that the quality of a product could 
be planned and the most quality inadequacies originate from the way in which the 
quality of the product was planned [4, 5].
In the pharmaceutical field, there are several regulatory guidelines developed 
by ICH, FDA, and EMA, which offer the necessary information in understanding 
how the QbD concept may be implemented [2, 3, 6–8]. In ICH Q8—Pharmaceutical 
Development guideline, QbD is defined as “a systematic approach to develop-
ment that begins with predefined objectives and emphasizes product and process 
understanding and process control, based on sound science and quality risk man-
agement” [9]. Such a scientific, risk-based, and pro-active approach from the devel-
opment to manufacturing of a pharmaceutical product will provide the necessary 
knowledge and information to minimize the risk and ensure a predefinite quality 
of the product [10]. So, QbD provides the tool to understand the way in which the 
quality of a pharmaceutical product is influenced by formulation, input materials’ 
characteristics, and process variables; therefore, the quality of the product can be 
ensured by controlling the formulation input materials and the manufacturing 
process key variables [2, 4, 11]. It involves designing a formulation and manufactur-
ing process in such a way to obtain a pharmaceutical product with predetermined 
quality specifications [12]. QbD identifies characteristics that are critical to quality 
of the product, translates them into attributes that the drug should possess, and 
establishes how the critical formulation and process parameters can be varied to 
constantly produce a drug product with the desired characteristics [13, 14]. The 
goal of the QbD approach is in-depth understanding of the formulation and process 
variables, and of the relationship between them, in order to obtain a drug product 
with consistent desired characteristics [15, 16]. Practically, QbD helps establishing 
the critical quality attributes (CQAs) of the product and how the critical mate-
rial attributes (CMAs) and critical process parameters (CPPs) can be modified to 
deliver a product with predetermined quality specifications [12].
A QbD approach includes several key steps, as follows: (1) defining the qual-
ity target product profile (QTPP); (2) performing a risk assessment, in order to 
identify which formulation, material, or process parameters can potentially influ-
ence the product’s quality attributes (CQAs); (3) studying the impact of the formu-
lation variables, material attributes, and process parameters on the critical quality 
attributes (CQAs) of the drug product, and finding which of them are critical 
material attributes (CMAs) and critical process parameters (CPPs); (4) establishing 
a design space that ensures desired product specifications; and (5) designing and 
implementing a control strategy in order to ensure a continuous improvement [9, 
17, 18]. In order to study the relationship between the CMAs and CPPs and their 
impact on CQAs in a mathematical form, the Design of Experiments (DoE) strategy 
is used. This method also allows to establish the design space by running a mini-
mum number of experiments [2, 11, 19]. The design space for liposome preparation 
may be established by implementing the QbD strategy as a systematic approach in 
liposome development, in order to improve the product quality, by understanding 
and controlling formulation, materials, and manufacturing variables. The strategy 
is recommended by the drug regulatory agencies for the development of better-
quality products and may be used in liposomal drug product development.
2.  Defining the QTPP for liposomal products and identification of the 
CQAs
The most important element in using QbD concept to assist formulation and 
process design is to predefine the desired final product quality profile [9, 14, 20]. 
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According to the definition of ICH, the QTPP is “a prospective summary of the 
quality characteristics of a drug product that ideally will be achieved to ensure the 
desired quality, taking into account safety and efficiency of the drug product” [9]. 
In order to establish the QTPP, the following considerations must be taken into 
account: route of administration, dosage form, dosage strength, delivery system, 
attributes affecting pharmacokinetic characteristics, stability, sterility, and drug 
release appropriate for the intended final product [14, 20].
QTPP is established based on prior scientific knowledge and appropriate in vivo 
relevance. According to the current flux of literature, a QTPP for liposomal prod-
ucts is presented in Table 1 along with the targets for each element [21].
When designing a nanoformulation, the efficiency of the final product will be 
directly related to particle size. Particle size is the most important factor influencing 
biodistribution, circulation half-life, and cellular uptake. Due to their small size 
and large surface area, pharmaceutical nanosystems show enhanced bioavailability 
and additional ability to cross the biological membranes. Furthermore, in cancer 
therapy, smart nanoparticles deliver the drug into the tumor tissue and avoid nor-
mal tissues and organs [22]. After intravenous administration, liposomes accumu-
late in tumors by a passive or active targeting, for determining higher therapeutic 
efficiency and less side effects [23]. As a parenteral dosage form, liposomal products 
must be sterile, pyrogen free, and well tolerated [24]. The lack of hemolytic activity 
is also mentioned as requirement for liposome products [25].
The second step in a QbD approach is the identification of CQAs. According to 
ICH Q8 definition, a CQA is a “physical, chemical, biological, or microbiological 
property or characteristic that should be within an appropriate limit, range, or 
distribution to ensure the desired product quality.” They are either derived from the 
QTPP or defined based on regulatory requirements and review of the literature [9].
Based on these recommendations, for the liposomal products the following 
CQAs are usually identified: mean particle size, size distribution, and zeta potential 
(as physical CQAs); drug content (as chemical CQAs); in vivo stability and drug 
release (as biological CQAs); sterility (as microbiological CQA).
a. Generally, for all nanoparticles, the mean particle size and particle size distribu-
tion are major CQAs, which play an important role in determining their in vivo 
distribution, drug loading, drug release, and targeting ability.
QTPP elements Target
Dosage form
Dosage design
Administration route
Nanoformulation
For targeted delivery
Parenteral
Quality attributes of 
the liposomal product
Biocompatibility
Microbiological quality
Bacterial endotoxins
Lack of hemolytic activity
Sterile
Free
Physical attributes (particle size and 
morphology, viscosity, zeta potential, 
osmolarity, appearance)
Drug identification
Drug content
In vivo stability
Drug release
Degradation products
Residual solvents
Must meet the standards resulted 
from the specifications of similar 
approved products or from the current 
scientific research
Table 1. 
QTPP of liposomal products.
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The biodistribution of nanoparticles circulating in the blood stream is con-
siderably influenced by particle size. Smaller particles, of 20–30 nm, are 
eliminated by kidneys, while larger particles, of up to 300 nm, are taken up 
by reticuloendothelial system (RES) [26]. By decreasing particle size below 
100 nm, RES uptake can be reduced [27]. According to other studies, the ideal 
nanocarriers should have particle size ranging between 10 and 100 nm in 
order to evade the kidney filtration and capture by the liver [28]. For example, 
in tumor targeting, the particles need to be smaller than the cut-off of the 
fenestrations in the tumor neovasculature [29]. The literature reveals that for 
an efficient enhanced permeability and retention (EPR) effect, the particle 
size must be, generally, between 50 and 100 nm, depending on the tumor 
type, its environment, and its localization [28]. Particle size less than 200 nm 
is also beneficial for the sterility of the liposomal product, since this size allows 
aseptic preparation and sterile filtration of the final product [30].
Particle size also influences the kinetics of drug release. As particle size gets 
smaller, their surface area-to-volume ratio gets larger. This would imply that 
more of the drug is closer to the surface of the particle compared to a larger 
particle. Being at or near the surface would lead to a faster drug release [23].
Polydispersity index, reflecting particle size distribution of liposomal prod-
ucts, is a physical parameter for which the target is to have reduced values, 
indicating a good homogeneity of the dispersion. Generally, polydispersity 
index values below 0.5 are reported to be acceptable [31].
b. Zeta potential or particle charge is an important parameter in the evaluation 
of colloidal system’s stability. Particles with a high negative or positive zeta 
potential value repel each other, indicating that the colloidal system is stable 
[32]. On the contrary, decreasing the zeta potential value to nearly neutral 
leads to liposomal aggregation [20]. The charge of nanosystems influences 
both systemic circulation time and the interactions with the target tissue. The 
presence of surface charge can alter the opsonization profile of the particles, its 
recognition by cells in the organs of the RES, and the overall plasma circulation 
profile [29]. Regarding the interaction with the target, it is known that cationic 
liposomes have affinity for negatively charged cancer cell membrane and 
higher selectivity than neutral or anionic liposomes. The intracellular uptake 
of cationic liposomes by tumor cells can be 14-fold higher than that of normal 
liposomes. Consequently, cationic liposomes enhance the safety of liposomal 
drug. The liposome charge can also influence drug loading, cationic liposomes 
exhibiting higher encapsulation efficiency for negatively charged drugs [32].
c. Depending on drug distribution in liposomal dispersion, the drug content of 
liposomes can be expressed in three ways: drug concentration (μg/mL); entrap-
ment efficiency (EE, the amount of drug contained inside liposomes compared 
with total amount of drug; %); and drug loading (the amount of drug con-
tained relative to the amount of the lipid used; drug-to-lipid ratio) [14, 20].
High encapsulation efficiency is very important for both manufacturers 
and patients. A higher percentage of drug encapsulation could reduce the 
manufacturing cost and increase drug concentration in the final formulation 
allowing greater flexibility in dosing. Depending on the pharmacokinetics, 
higher drug concentration can result in increased dosing intervals and hence 
improved patient compliance [30].
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Drug retention inside liposomes is also very important. Since liposomes are 
intended to deliver the drug to the target site, there should be no drug leakage 
until cellular uptake [30].
d. In order to have a prolonged drug release and an efficient tumor accumulation 
by passive targeting, in vivo stability is essential. In vivo behavior of liposomes 
after intravenous administration is directly linked to their interaction with blood 
components, which depends on the hydrophobic/hydrophilic character of lipo-
some surface. The more hydrophobic a nanoparticle is, the more likely it is to be 
cleared by phagocytosis, due to higher binding of blood proteins (opsonization) 
[22]. The improved surface properties are associated with the steric hindrance 
effect offered by hydrophilic polymers, which can prevent the surface-modified 
liposomes from being rapidly eliminated by RES (“stealth liposomes”). 
Hydrophilization of liposome surface prolongs circulation time (long-circulat-
ing liposomes), enhancing the therapeutic potential of the entrapped drug [33].
e. Drug release kinetics has important implication for the therapeutic activity of 
liposomes. The drug must be delivered to the disease site at a level within its 
therapeutic window, at a sufficient rate, for a sufficient period, to have optimal 
therapeutic activity [34]. Drug delivery to the right site is related to the iden-
tification and the interaction with the target cells. Cell surface or blood vessel 
surface of tumor tissues has a series of specific and overexpressed receptors, 
which are closely related with tumor process [33]. Targeting ligands attached 
on liposomes’ surface bind the corresponding receptors and, as a result, the 
liposomes are internalized by endocytosis. These ligands can be monoclonal 
antibodies, fragments of antibodies, peptides, proteins, nucleic acids, carbohy-
drates, or small molecules [29].
3.  The critical material attributes and critical process parameters: 
identification and linking to CQAs
All the material attributes (MAs) and/or process parameters (PPs) that can 
affect the desired critical quality attributes (CQAs) of the final/intermediate prod-
uct are identified through risk assessment. After risk identification, risk analysis 
evaluates the impact of the identified MAs and PPs on the CQAs. Further, through 
risk evaluation, a qualitative or quantitative scale is used for risk estimation of each 
identified factor on the desired CQA [35]. After the risk evaluation of potential MAs 
and PPs, only few of them will become potentially critical for quality attributes of 
the final drug product. In this case, identified MAs will become critical material 
attributes (CMAs), which must possess certain characteristics or should be chosen 
in an appropriate range to assure CQAs of the intermediate/final drug product 
[21]. Critical process parameters (CPPs) are those PPs that should be monitored 
and controlled in order to obtain the desired CQAs of the intermediate/final drug 
product [9]. Many tools are used for risk assessment, but the most used ones are 
Ishikawa or fish-bone diagram for risk identification and failure mode and effect 
analysis for risk evaluation [36]. Risk assessment should be done in the first step of 
the drug product development, and analysis of these risk factors is recommended to 
be reconsidered during different stages of the drug development [37].
To establish the CMAs, the main components of liposomes are evaluated, that 
is the active substance, the lipids, and others like buffer solution [38]. Each active 
substance has different physiochemical properties and can influence the desired 
CQAs [9, 39]. Depending on its solubility, it can be entrapped in the aqueous core 
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or in the lipid bilayer [40]. In order to achieve a greater therapeutic effect, more 
than one active substance may be encapsulated in the same product, so different 
physiochemical properties of one may influence the other/others drug entrapment 
process [40, 41]. Besides this, their octanol/buffer partition must also be taken into 
consideration because a low partition will lead to a prolonged release of the drug 
and vice versa [42].
Regarding the lipids, their physicochemical characteristics are also important. 
For example, lipids that contain unsaturated fatty acids are predisposed to degrada-
tion reactions like oxidation or hydrolysis and those which contain saturated fatty 
acids have a higher transition temperature (Tm) [43]. Another specific characteristic 
of lipids is their chain length. Usually, a shorter chain length will contribute to a 
thinner lipid bilayer and a larger internal volume for drug encapsulation. However, 
comparing three lipids with a difference of two carbon atoms between them, the 
lipid bilayer thickness obtained did not differ with more than 1 nm and a very small 
difference in liposomes’ size and EE was observed [30]. Lipid properties can have a 
great impact on liposomes’ membrane fluidity, permeability, or charge [44]. In this 
regard, cholesterol increases liposomal stability, reduces membrane fluidity, and, 
consequently, contributes to an increased EE [45].
Different compounds used for surface modification, in order to obtain a pro-
longed blood circulation or modified drug release, must be evaluated during risk 
identification and analysis. For example, when chitosan was used for coating, its 
concentration, solubility, and molecular weight influenced liposomal size [46]. In 
the case of polyethylene glycols (PEGs), the molecular weight and the density on 
liposomal surface influenced the biodistribution and size [47].
Besides the nature of liposomal components, their concentration and ratios 
between them are also critical. Some of these ratios, identified in risk assessments 
of different studies, are: organic phase-to-aqueous phase ratio; cholesterol-to-
lecithin ratio; chloroform-to-methanol ratio; phospholipids-to-cholesterol molar 
ratio; and drug-to-lipid ratio [40, 46, 48, 49].
Regarding the preparation process, many techniques and methods like film 
hydration, emulsification, and reverse phase evaporation were developed but the 
most used one remains the film hydration method [37]. For this method to be 
efficient from the viewpoint of EE, parameters like temperature or rotation speed 
in the evaporation and hydration steps are critical and must be optimized [41, 49]. 
Film hydration method’s great disadvantage is that the obtained liposomes are in 
the vast majority of micron size with a multilamellar structure, being characterized 
by a high percentage of lipids and a reduced internal volume. Thus, a reduction in 
particle size is mandatory, to increase their internal volume and to have a controlled 
size and narrow particle size distribution [30, 37]. For reduction of liposomal size, 
several techniques like sonication, freeze-thaw cycling, or extrusion may be used. 
Comparing these size-reduction methods through a screening experimental design, 
they were found to be critical for particle size distribution but also for EE [30]. 
When extrusion through membranes is used for size reduction, membrane pore 
size, temperature, and applied pressure are important CPPs because these factors 
define the final particle size and can seriously influence the final EE [30]. Sonication 
process also needs optimization as regards its time in order to achieve the desired 
liposomal size [46]. For the freeze-thaw cycling process, the number of the cycles 
might be taken into consideration for further optimization in order to get the desired 
particle size [30].
After the risk assessment, next step in QbD development is linking the identi-
fied CMAs and CPPs to CQAs by using Design of Experiments (DoE). The greatest 
advantage of using DoE is that it can track the interactions between the studied fac-
tors, CMAs and CPPs, and it can establish a quantitative relationship between the 
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identified variables and the results [36]. For a better understanding of this concept 
in liposomes development, the most important CQAs will be discussed further, and 
how CMAs and CPPs can influence them according to different studies.
3.1 Drug content
The drug content is most frequently optimized in terms of EE than drug concen-
tration as EE reflects better the preparation process performance and robustness. 
According to published data, the most influential factors for EE are: the amount 
of drug and phospholipids; cholesterol concentration; the nature of lipids and 
drug; the interactions between different components; the lipid-to-drug ratio; and 
several process parameters. Among these, several studies established, through 
DoE approaches, that lipid molar ratio and lipid-to-drug ratio are the most critical 
parameters for EE optimization. Using a great amount of lipids for liposome prepa-
ration favors the formation of many vesicles with a significant internal volume for 
drug encapsulation and, consequently, the EE of hydrophilic drugs increases [30, 
45]. Including cholesterol in liposome formulations increases not only their stabil-
ity but also the drug content, due to the so-called “pocket” theory, presuming that 
cholesterol can generate different size pockets inside the lipid bilayer where API can 
be entrapped [45]. The use of unsaturated lipids was shown to have a similar effect, 
the unsaturated lipids forming pockets inside the lipid bilayer where lipophilic 
drugs can be entrapped [50]. By increasing lipid-to-drug ratio from 1:1 to 10:1, 
the EE of ritonavir, a lipophilic drug, was doubled from 45 to 90% [43]. The ratio 
between phospholipid concentration and drug concentration was demonstrated to 
have a significant impact on EE in the case of simvastatin. Thus, at high simvastatin 
concentration and low concentration of phospholipids, EE decreased [51].
In the case of drugs with pH-dependent solubility like doxorubicin, the EE can 
be improved by the use of active loading method at specific pH range, the pH of 
hydrating buffer and of external buffer being critical parameters [52].
Regarding the drug concentration, several studies concluded that the total 
amount of drug used for encapsulation has a breaking point from which the EE 
cannot be further increased [41, 46].
EE may also be influenced by PPs. A fractional factorial design was used to 
establish the link between PPs like hydration temperature and the number of 
freeze-thaw cycles during preparation of liposomes loaded with FK50, an immu-
nosuppressant. An interaction between these PPs was highlighted. It was observed 
that by using an increased number of cycles, and high hydration temperature, EE 
decreased, because repetition of the freeze-thaw cycle at high temperature might 
induce leakage of FK506 from the membrane of the liposomes [39]. In another 
study, it was observed that PPs like temperature during film hydration and rotation 
speed during solvent evaporation are critical. Using high temperature, above Tm, the 
concentration of the encapsulated drug increases because at high temperature, the 
lipid bilayer is more fluid and permits the entrapment of more drug. Also, using a 
high rotation speed at the film formation can have a great impact on EE because this 
CPP leads to formation of a thinner lipid bilayer which can easily be hydrated [53].
3.2 Particle size and size distribution
Maintaining a controlled particle size and low PDI is one of the main challenges 
when preparing liposomes, and optimization of these parameters is improved 
through the use of DoE. There are many critical factors influencing these param-
eters, both formulation and process related. For example, the influence of phospho-
lipid concentration, active substances (curcumin and doxorubicin) concentration, 
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working temperature, buffer pH, and phospholipid-to-cholesterol ratio, on 
liposomal size, was examined through a screening experimental design. Out of the 
studied factors, only phospholipid concentration and phospholipid-to-cholesterol 
ratio significantly influenced the size, while the concentration of the drugs and 
the working conditions were not critical for particle size. Noteworthy, none of the 
studied parameters influenced particle size distribution [41].
Regarding the effect of lipid concentration, different studies showed contradic-
tory results on the size in relation to this factor [43, 46]. Usually, on increasing 
lipid concentration, liposomal size increases, simultaneously with PDI values [54]. 
Another observation was that increasing lipid concentration over a certain value 
leads to smaller size, probably due to lipid bilayer rearrangement into a bigger 
number of liposomes with smaller size and better size distribution [55]. Depending 
on the lipid type, a different influence on liposomal size was observed [56].
The active substances influence liposomal size depending on their physico-
chemical properties. It was observed that quercetin, a lipophilic compound, might 
replace some lipids in the lipid bilayer causing a reduction in size when it is used in 
high concentrations [55]. On the other hand, high concentrations of pravastatin, 
a hydrosoluble compound, led to a small size of liposomes due to an interaction 
between the active substance and the lipids [53].
3.3 Zeta potential
This parameter is influenced by formulation factors like ionic strength, pH, 
bilayer composition, or charged lipids and PPs like sonication time [48, 57]. In order 
to modulate the ZP values, different stabilizers, such as stearylamine and diacetyl 
phosphate, or modified lipids, such as poly(2-ethyl-2-oxazoline) (PEtOz) or PEG, 
can be incorporated in lipid bilayer. The concentration of these excipients may be 
optimized such as to obtain optimal stability [50, 57]. In conventional liposomes, 
cholesterol-to-lecithin ratio influences the zeta potential value [48]. Through DoE, 
several papers established the critical parameters influencing the zeta potential 
values. For example, a screening design study was used to determine which of 
the formulation factors (lipid concentration, cholesterol concentration, chitosan 
concentration, drug concentration, organic phase/aqueous phase ratio) and process 
parameters (temperature, stirring speed, sonication time) had a significant influ-
ence on zeta potential of chitosan-coated liposomes. As expected, chitosan con-
centration was a critical parameter, along with the temperature, which favored the 
coating process through reduction of vesicles size [46].
3.4 In vivo stability and drug release
By choosing a suitable lipid bilayer composition, a higher stability in vivo might 
be achieved. In order to sustain this, it was observed that using saturated lipids 
or cholesterol in formulations, lipid bilayer stability is increased and liposomal 
uptake by mononuclear phagocyte system will be reduced. Another used pathway 
is incorporation of different excipients, such as ganglioside GM1, phosphatidylino-
sitol or PEG-lipids, creating a steric barrier which prevents their clearance from the 
system [42]. The organs in which liposomes accumulate for being eliminated are 
lungs, liver, spleen, and kidneys. It was observed that those liposomes with negative 
surface charge present a higher uptake in tumor cells and a slower uptake in liver 
cells [58]. In a study, four liposome formulations were compared regarding their 
in vivo stability, by tracking their accumulation in spleen. Results showed that the 
molecular weight of PEG attached to their surface as well as particle size were CMAs 
influencing the accumulation in the spleen [47].
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Depending on the lipophilic or hydrophilic character of the active substance, the 
kinetics of release is different because the diffusion through liposomal membrane 
is influenced by its physiochemical properties [41]. This behavior was shown when 
the release of two different lipophilic drugs and a hydrophilic drug from the same 
liposomal system was studied in vitro. The lipophilic agent displayed prolonged 
release and a smaller total drug release in comparison with the hydrophilic one due 
to their different characteristics [40].
For pH-sensitive liposomes, the objective in terms of in vitro drug release is to 
have a very good stability of the encapsulated drug under physiological conditions 
and triggered drug release at certain pH values. To achieve this, the use of excipi-
ents having a membrane-destabilizing effect and their concentration are critical 
parameters [52, 56].
4. Defining the product and process design space
The design space (DS) is a multidimensional combination and interaction of 
the input variables, such as material attributes, and process parameters that have 
been shown to assure quality [9]. Thus, the advantage of DS determination is that it 
establishes the operating region which ensures consistent product qualities between 
different batches. Working within the DS, the product will meet the specifications 
mentioned in the QTPP, while moving out of it is considered a change that would 
normally require a regulatory approval in the case of authorized products [9].
Determination of the DS is based on multivariate analysis, considering the main 
effects of factors as well as their interaction, which helps in determining an opera-
tional region based on a predefined confidence level. The DS includes the product 
design space and process design space. The product DS is established with product’s 
CQAs as dimensions, while the process design space is exhibited as CQAs with 
respect to CPPs [59].
One approach to establish the DS for liposomal products is to take simultane-
ously into consideration both formulation factors and CPPs. This method was 
used for the determination of the DS for lyophilized liposomes with simvastatin. 
Thus, the cholesterol concentration, the PEG proportion, the cryoprotectant-to-
phospholipids molar ratio, and the number of extrusions through polycarbonate 
membranes were selected as the most influential factors for lyophilized liposome 
CQAs. Their variation range was determined, in which the established quality 
requirements of the product are met: reduced particle size, maximized drug reten-
tion during lyophilization, reduced change in phospholipid transition temperature, 
low residual moisture content. The validity of the DS was confirmed by determin-
ing the CQAs of a formulation corresponding to the robust set point, that is, the 
formulation for which the prediction errors are lowest. Thus, defining the DS was 
found to be a useful strategy for the development of stable lyophilized liposomes 
having predictable quality [60]. The same approach was used to generate the DS for 
preparation of prednisolon-loaded long-circulating liposomes at laboratory scale. 
In this case, the selected formulation parameters were prednisolon concentration 
and the PEG proportion in lipidic membrane, and the process parameters were the 
extrusion temperature and the rotation speed at the hydration of the lipid film. The 
DS was developed such as to ensure high liposomal drug concentration, high EE, 
and controlled size [49].
When process parameters are not found as critical for the quality of the product, 
or their impact on quality is easily controlled by fixing a certain operating level, the 
DS is proposed as a function of formulation variables. This approach has been used 
in several studies, the most studied formulation variables being the active substance 
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concentration and the composition of the lipid membrane. For example, the DS for 
liposomes with tenofovir was constructed with respect to phospholipid, concentra-
tion, cholesterol concentration, and drug concentration, with a focus to obtain high 
drug encapsulation efficiency, as this was considered the most difficult property 
to predict and control for liposomes containing hydrophilic drugs. Other quality 
attributes considered critical in the study, particle size and stability, were controlled 
by the pore size of the extrusion membrane and by storing the samples at low tem-
perature, respectively [61]. In another paper, the DS for chitosan-coated liposomes 
was established as a function of drug concentration, chitosan concentration, and 
the organic phase-to-aqueous phase ratio during liposome preparation by ethanol 
injection technique. These variables were found to be the only significant factors 
affecting the CQAs of the product, although other formulation and process param-
eters were evaluated through a screening study. The composite desirability function 
based on constraints was used to determine the conditions that would result in an 
optimal formulation design, in terms of particle size, encapsulation efficiency, and 
coating efficiency. Target values were selected for the mentioned quality attributes, 
and, on the basis of these target values, the optimum values for each variable or 
processing parameter were obtained. In an additional step, the robustness of the DS 
was analyzed and the results showed that the selected CPPs may help minimize the 
variations in QAs that might arise due to the variability of the raw materials [46].
The development of liposomal systems entrapping more than one active sub-
stances is more complex, because the properties of each will influence the CQAs of 
the product and their stability in the processing conditions will impact the process 
parameters. In this regard, a group of authors established and evaluated the DS for 
long-circulating liposomes co-encapsulated with curcumin and doxorubicin. DS 
development was based on a previous screening study, which revealed the critical 
parameters, that is, phospholipid concentration, the phospholipid-to-cholesterol 
molar ratio, doxorubicin concentration, and curcumin concentration. The purpose 
was to obtain the variation range of these factors for which the size of the liposomes 
is minimized and the encapsulation efficiencies of both drugs are maximized. The 
DS was established as the region within which the prediction of the CQAs is made 
with a probability of failure of less than 1%. Moreover, a DS hypercube was set out 
as a restricted zone in the DS where factors’ values can vary independent of each 
other, without influencing the quality of the product [41].
The incomplete understanding of the manufacturing process is a major bar-
rier in liposomal products’ industrial production and clinical application. The 
destabilization of their structure during long-time storage as aqueous dispersions 
revealed the need for complex fabrication processes, involving drying steps such as 
lyophilization and spray drying. The key to the successful design and preparation of 
optimal liposomal dry powder formulations is an understanding of the significance 
of the drying process parameters [62]. This aim was achieved by several authors by 
determining the DS for lyophilization or spray drying process.
The DS for the freeze-drying process of pravastatin-loaded long-circulating 
liposomes was established as a function of the freezing rate and shelf temperature 
during primary drying. The two process parameters were found to have a great 
impact on product’s CQAs, along with the presence of an annealing step. The condi-
tions to obtain freeze-dried liposomes with the desired characteristics were gener-
ated using the combination trehalose-mannitol as cryoprotectant and by including 
an annealing step. A series of limitations and target values were applied for the criti-
cal quality attributes of the lyophilized product. Thus, the DS was constructed such 
as to ensure high drug retention after lyophilization, particle size below a certain 
value, low zeta potential, low residual moisture content, and a short duration of the 
primary drying. Out of the DS, an optimal formulation was selected and testing this 
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formulation confirmed that the process delivers the desired quality of the product, 
as long as it is operated within the DS [63].
A process design space for spray drying of liposomes was developed such as to 
get a product that met the criteria for all CQAs of an inhalable powder formulation. 
When developing an inhalable product, the mass median aerodynamic diameter 
(MMAD) is the most important CQA, as this characteristic influences the deposi-
tion in the conducting airway. Besides this, the size stabilization, relative moisture 
content, and process yield were identified as CQAs. The DS was plotted by impos-
ing restrictions especially for MMAD, which should be within the range 4.5–5.5 μm, 
but also for liposome size ratio (before/after drying) and the yield of the process, 
while for moisture content, no restrictions were set, as acceptably low values were 
obtained for all the experiments. First, an optimal operating space (OOS) was 
identified with a high feed flow rate, a low outlet temperature, a medium aspirator 
rate and in the area of low feedstock concentration and high atomizing airflow. The 
MMAD was the QA restricting the entire ODS to the low feedstock concentration 
and high atomizing airflow, whereas the other CQAs met the imposed criteria in a 
larger space [64].
5. The control strategy
Due to the great success of liposomal systems, not only in pharmaceutical 
formulation but also in cosmetics and food industry, there is a huge demand on 
developing and standardizing analytical and bioanalytical methods for liposome 
complete characterization, as well as for their detection in blood and tissues. 
Official guidance regarding the manufacturing and controls recommend several 
methods for lipid components as well as for the drug products [65]. According to 
FDA guideline, “liposome structures and integrity are important physicochemical 
properties and they reflect the ability of the liposome drug formulation to contain 
the drug substance and to retain the drug substance within the appropriate lipo-
some structure” [65].
A key issue in the control of liposomes is closely related with the quality control 
of the lipid components, including modified lipids, which could dramatically influ-
ence the properties and performances of liposome drug product [65]. The quality 
of the final product is influenced by the source of lipids and also by the type of the 
lipids: synthetic, semi-synthetic, or natural.
All types of separation methods, such as gas chromatography (GC) or liquid 
chromatography (LC), capillary electrophoresis (CE), gel electrophoresis, or 
electrochromatography have proved their value in the analysis of lipid components 
of liposomes [66–68]. In order to evaluate the chemical stability of the liposomes, 
it is mandatory to assess the chemical stability of the lipid components in the final 
drug formulation, taking into account that some lipids could be degraded by oxida-
tion or hydrolysis. From the practical point of view, most of the separation methods 
offer important information on this matter. The broad versatility, high selectivity, 
efficiency, and low time of analysis are making them a good choice.
While the analysis of lipids using liquid chromatography does not need a long 
stage of pretreatment, the lipids analyzed using gas chromatography have to be 
derivatized in order to obtain more volatile compounds which are not turning into 
degradation products at their boiling point [69]. For fatty acids, the most used 
derivatization method consists in the esterification of the acids and their transfor-
mation in methyl esters. The esterification takes place under various conditions of 
temperature, mixing process, using different catalysts and for various periods of 
time. There are plenty of studies among scientific literature about derivatization 
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methods of fatty acids for their GC analysis, researchers being still interested in 
improving the pretreatment of these compounds to obtain an efficient and rapid 
process [70].
Even though the literature abounds in examples of separation techniques applied 
for lipid detection and quantification, some drawbacks are obvious: poor solubil-
ity, poor absorbance properties, the need for derivatization, and laborious sample 
preparations. Nevertheless, the hyphenation between techniques could overcome 
the drawbacks and offers promising results.
Regarding the control of the final product, the following properties are gener-
ally determined to characterize a liposome drug formulation: morphology; surface 
charge (expressed as zeta potential); particle size (average diameter) and polydis-
persity index; encapsulation efficiency; the amount of drug relative to the amount 
of lipids; phase transition; residual solvents; in vitro and in vivo drug release [71]. 
Variability in these properties may lead to changes in the quality of the liposomal 
drug products, including leakage of the drug from the liposomes. The QAs moni-
tored for liposomes are presented in Table 2, together with the currently employed 
methods of analysis.
Particle size is one of the crucial parameters for further in vivo application of 
liposomes. The required size is usually in the range 20–250 nm. When using micros-
copy techniques, one will obtain a high-resolution three-dimensional profile of the 
vesicle surface under study. For instance, AFM permits liposomes’ visualization 
without alteration of their native form, given that the requisite surface immobiliza-
tion does not adversely affect the sample and that the force of the probe itself does 
not have deleterious effects on the vesicles [75]. AFM is a rapid, powerful, and 
relatively non invasive technique and compared to TEM, does not requiers compli-
cated sample preparation and removal of liposomes from their native environment. 
Additionally, TEM provides information on the size distribution and shape of 
vesicles. Unfortunately, liposomes can suffer from structure perturbations triggered 
by the high vacuum conditions and the staining process.
The investigated property Methods Ref.
Morphology UV-vis spectroscopy
Spectrofluorimetry
RMN
Angle X-ray scattering (SAXS)
Freeze fracture technique with subsequent transmission 
electron microscopy
[71–73]
Net charge (zeta potential) ELS [74]
Particle size Microscopy techniques (TEM, AFM, SEM)
SEC
Field-flow fractionation and static
DLS
[74, 75]
Drug encapsulation efficiency Spectroscopy
LC
[75]
In vitro drug release Spectroscopy
LC
[75]
In vivo drug release Radiolabeling, fluorescence labeling, MRI, CT, MS [75]
AFM, atomic force microscopy; TEM, transmission electron microscopy; SEM, scanning electron microscopy; ELS, 
electrophoretic light scattering; LC, liquid chromatography; SEC, size-exclusion chromatography; DLS, dynamic 
light scattering; MRI, magnetic resonance imaging; CT, computed tomography; MS, mass spectrometry.
Table 2. 
The quality attributes monitored for liposomal products.
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To measure particle size and size distribution, three types of techniques 
could be used: all together, separation, and particle-by-particle counting. In the 
first case, multi-angle (static) and dynamic light scattering (MALS and DLS, 
respectively) techniques permit the calculation of the average particle size and 
charge from the signal generated by multiple particles within the sample. Even 
though these techniques are fast, they have low resolution and do not provide 
the particle concentration. Separation techniques, such as disk centrifuge and 
field-flow fractionation, have the advantage of improving size analysis resolution 
by using differences in the sample properties, typically sedimentation rates, to 
pre-separate the sample prior to light-based (absorbance or scattering) analysis. 
The separation techniques do not measure particle concentration or charge, and 
they often suffer from separation-based issues. More effective are particle-by-
particle counting techniques, such as tunable resistive pulse sensors (TRPSs). 
The main advantage is the possibility to measure the properties of individual 
liposomes, offering a direct measurement of the particle concentration as well as 
high resolution and more accurate analysis of the particle size and charge (zeta 
potential) distribution. This ability to simultaneously measure the distribution of 
both the size and zeta potential represents a new and effective means of analyzing 
liposome properties [76].
To measure the zeta potential, ELS technique is currently used. It consist in 
using heterodyne scattering methods in which a fraction of the laser beam is split 
away by a mirror before reaching the sample, and is directed to the detector where it 
is combined with scattered light from particles diffusing in the sample. The frac-
tion of redirected light is referred to as the “local oscillator” and, unlike the light 
scattered by the sample, does not fluctuate. It is used as a reference beam and must 
be much larger than the average intensity of the scattered light produced by the dif-
fusing particles. To determine the zeta potential, the electrophoretic mobility must 
first be ascertained [77].
The surface modification of liposomes is sometimes performed in order to 
increase their in vivo drug-delivery performances. As mentioned earlier, several 
ways of modifying the surfaces were reported, like the addition of polyethylene 
glycol (PEG) chains, or the attachment of antibodies and cellular receptor recogni-
tion molecules (e.g., the RGD peptide) as molecular targeting probes. Tracking the 
successful modification of liposomes is made by measuring the change in their elec-
trophoretic mobility, in fact the modification of their zeta potential arising from the 
change in the number of charged surface groups. Another method for measuring 
the zeta potential of liposome particles is via ensemble light scattering techniques, 
which use a similar principle as DLS [78].
Within the control strategy, process analytical technology (PAT) has been evi-
denced lately as a significant tool for measuring parameters and attributes related 
to the active substance, the finished product as well as the processing conditions. 
Among the PAT tools, in the field of liposomes, near-infrared spectroscopy (NIRs) 
has been shown to be useful for the chemical characterization of liposomes in terms 
of the composition of the lipid membrane, as well as for the simultaneous quantifi-
cation of excipients and active substance [79, 80].
Besides the large-scale production, which is a major challenge, the standardiza-
tion of analysis procedures easily scalable is another important goal in practical 
application of liposomes. The liposome production is done in small size batches 
compared with other pharmaceutical products which are produced in large batches 
[71]. However, the possible application of liposomes and the increasing number of 
clinical trials involving liposomes prove the fact that this field of research is very 
dynamic and the synthesis and analysis methods become more effective, encourag-
ing their application in the development of new drug carriers.
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6. Conclusions
The implementation of the QbD approach in the pharmaceutical industry is 
intended to enhance the quality of pharmaceutical products through identifying, 
analyzing, and controlling all factors that could alter their quality, and, conse-
quently, its efficacy and safety. Currently, an increasing number of papers describe 
the development of liposomal products based on this risk-based approach, although 
only few are following all the steps recommended by the regulatory guidelines. 
Finally, this strategy could be useful to promote liposomes from laboratory into 
authorized products.
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